You just read:

Janssen Inc. Announces Health Canada Approval of TREMFYA™ (guselkumab) for the Treatment of Adult Moderate to Severe Plaque Psoriasis

News provided by

Janssen Inc.

Nov 15, 2017, 08:00 ET